You are currently viewing the summary.
View Full TextVia AAAS ID
This article is available to AAAS members. If you are a AAAS Member use your via AAAS ID and password to log in. Not a member? Click here to join.
Summary
European countries are embroiled in a debate over how to redo rules for clinical trials, an effort to replace a controversial 12-year-old directive that critics say bound human research studies in red tape. But preserving stringent patient protections without tipping into excessive bureaucracy—and getting 27 countries to agree—is no easy task.
